"I am excited with the Innocoll products and am impressed with the thorough and well-thought out development plans in place. I look forward to working with the board and management to move the Innocoll portfolio forward to commercialization," said Dr. Wild.
About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on
biodegradable surgical implants and topically applied healthcare products.
It develops and manufactures a range of pharmaceutical products and medical
devices using its proprietary collagen-based technologies, CollaRx(R) and
Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the
treatment and prevention of surgical site infections, is approved for sale
in 49 countries in Europe, Latin America, Middle East, Africa and Asia and
is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R)
EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R),
GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In
2005, Innocoll acquired the worldwide marketing rights for this product
from Essex Chemis AG, an affiliated company of Schering-Plough Corporation
(NYSE: SGP) and in August 2007 sold its marketing rights, with the
exception of the US, to EUSA Pharma. Gentamicin Surgical Implant is
currently in phase 3 development in the US for the prevention of surgical
site infections. Other late stage pharmaceutical products in Innocoll's
development pipeline include CollaRx Gentamicin Topical for the treatment
and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine
Implant for the management of post-operative pain, both of which are
currently in Phase 2 development. For more information, plea
|SOURCE Innocoll Inc.|
Copyright©2008 PR Newswire.
All rights reserved